Bausch Health Companies Inc.

PharmaceuticalsFounded 1994

Market Data Current As Of: September 12, 2026

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Explore Bausch Health Companies

Core profile pages, annual revenue records, and related research hubs for this company.

Bausch Health Companies Inc.

PharmaceuticalsFounded 1994

Reviewed by Swet Parvadiya

Last reviewed: September 12, 2026

Market Data Current As Of: September 12, 2026

Company History

Bausch Health Companies: Founding, Growth & Key Milestones

Founded 1994 in Laval, Quebec, Canada

Founding Story

The company that became Bausch Health started not as a pharmaceutical giant but as a small Canadian firm called ICO Corporation, incorporated in 1994. The 2015 collapse began with a congressional hearing where Senator Bernie Sanders displayed a chart showing Valeant's price increases on heart drugs, followed by a Citron Research report questioning the company's accounting and its relationship with the specialty pharmacy Philidor. Pearson was replaced by Joseph Papa, who began the process of shedding assets, cutting debt, and rebuilding relationships with the medical community.

Founders

J. Michael Pearson

Bausch Health, in its current corporate structure, is the result of M&A, but its foundational DNA and its namesake trace back to two distinct, innovative entities: ICN Pharmaceuticals (the predecessor to Valeant) and Bausch & Lomb (its former crown jewel). The original corporate entity, ICN Pharmaceuticals, was founded in 1960 by Milan Panić, a brilliant, charismatic Yugoslavian immigrant who had fled the Communist regime with only $200 in his pocket. Panić possessed a Ph.D. in chemistry and a profound entrepreneurial drive. He founded ICN in a Los Angeles garage and transformed it into a global pharmaceutical company. His defining scientific and commercial triumph was the development of Ribavirin in 1972, a groundbreaking broad-spectrum antiviral drug that proved effective against severe respiratory syncytial virus (RSV) and later became a foundational treatment for Hepatitis C. Panić led ICN for four decades, building an empire before being ousted in 2002 by activist investors, after which the company was renamed Valeant Pharmaceuticals. The other half of the company's historical DNA, Bausch & Lomb, was founded over a century earlier, in 1853, in Rochester, New York, by two German immigrants: John Jacob Bausch, an optician, and Henry Lomb, his financier and friend who lent him $60 to keep the struggling optical shop afloat. Bausch & Lomb became a titan of American optics, producing everything from the camera lenses that took the first satellite photos of the moon, to the invention of Ray-Ban Aviator sunglasses for the US military, to pioneering the first soft contact lenses in 1971. While Bausch Health recently spun off Bausch & Lomb into an independent company it is the profound, century-long legacy of those two German opticians that ultimately saved the Valeant conglomerate from total annihilation.

Key Milestones

1994

Founding of ICO Corporation

The corporate lineage of Bausch Health began with the founding of ICO Corporation in Canada, which later merged with Biolyse Pharma to form the foundation of the modern entity.

2001

Rebranding to Valeant Pharmaceuticals

Biolyse Pharma changed its name to Valeant Pharmaceuticals, marking the beginning of the aggressive acquisition-driven strategy that would define the company for the next two decades.

2008

Acquisition of Coria Laboratories

Valeant acquired Coria Laboratories for $350 million, securing a diversified portfolio of dermatology brands and establishing a foothold in the lucrative topical therapeutics market.

2010

Acquisition of Biovail

Valeant merged with Biovail in a reverse merger transaction, creating a significantly larger entity with enhanced manufacturing capabilities and a broader international footprint.

2015

Valeant Pricing Scandal and Stock Collapse

Following a Citron Research short-seller report and a subsequent SEC investigation, Valeant's stock price collapsed by 96%, forcing the ousting of CEO J. Michael Pearson and the complete restructuring of the board.

2016

Acquisition of Salix Pharmaceuticals

Valeant acquired Salix Pharmaceuticals for $10.3 billion, securing the Xifaxan franchise and establishing a dominant position in the gastroenterology market.

2018

Rebranding to Bausch Health Companies

Valeant Pharmaceuticals officially changed its name to Bausch Health Companies Inc., attempting to distance the corporate identity from the toxic legacy of the Valeant era.

2019

Acquisition of Ortho Dermatologics

Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, significantly expanding its presence in the acne and psoriasis markets.

2020

Acquisition of Dermira

Bausch Health acquired Dermira for $1.2 billion, securing the proprietary olumacostat glasaretil asset and expanding its pipeline in the dermatology space.

2022

Spin-off of Bausch + Lomb

Bausch Health completed the Bausch + Lomb public listing, creating a strategic separation path while Bausch + Lomb continued to be reported as a consolidated segment in later filings.

2024

FY2025 Financial Results

Bausch Health reported $10.266B in FY2025 consolidated revenue, $1.813B in operating income, and $3.54B in adjusted EBITDA attributable to Bausch Health.

Major Acquisitions

Dermira, Inc.

2020

Bausch Health acquired Dermira for $1.2 billion to gain control of the proprietary olumacostat glasaretil asset, a first-in-class topical inhibitor of sebaceous lipase for the treatment of acne vulgaris.

Ortho Dermatologics

2019

Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, securing a diversified portfolio of topical acne and psoriasis therapies, including Epsolay and Wynzora.

Salix Pharmaceuticals

2016

Valeant Pharmaceuticals acquired Salix Pharmaceuticals for $10.3 billion to gain control of the Xifaxan franchise, establishing a dominant position in the gastroenterology market.

Bausch Health Companies Company History FAQ

What are the defining historical milestones for Bausch Health Companies Inc.?

Since its establishment in 1994, Bausch Health Companies Inc. expanded from an early-stage venture into a recognized leader in Pharmaceuticals, overcoming key market challenges.

What major strategic pivots shaped Bausch Health Companies Inc.'s evolution?

Over its history, Bausch Health Companies Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.

How has Bausch Health Companies Inc. adapted to recent industry disruptions?

By continually modernizing operations and embracing workflow automation, Bausch Health Companies Inc. maintains resilience through changing technological and economic cycles.